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The gastrointestinal immune system is exposed to a large
amount of different products mainly innocuous (derived
from “friendly” bacteria and/or food antigens) but some-
times also dangerous and infectious (as invading bacteria
or viruses). Despite that, it is effective in discriminating
between them and hence maintaining immune tolerance
against the natural inhabitants of our gut, but initiating
immune responses against the harmful invading microor-
ganisms [1, 2]. In the last decades, the western lifestyle has
seen an increase in the prevalence of immunoregulatory dis-
orders which has been linked to changes in the microbiota
composition due to the increased use of antibiotics and the
absence of intestinal parasites as proposed in the “hygiene
hypothesis.” Indeed, the immune system has become more
dependent upon themicrobiota and the natural environment
[3]. However, recent data indicate that helminth-induced
immunomodulation occurs independently of changes in the
microbiota [4].
The commensal microbiota plays a central role modulat-
ing the outcome of immune responses in the gastrointestinal
tract keeping immune homeostasis in health [5]. Indeed,
germ-free animals have an immature immune system and can
develop inflammation which is reverted once the microbiota
is conventionalized [6]. The commensal microbiota also has
the capacity to modulate several aspects of the host including
its physiology and/or nutritional status contributing therefore
to several diseases affecting not only the gut but also distant
organs [7–9]. Therefore, not surprisingly the gut microbiota
modulation (via pre/probiotics or through faecal microbiota
transplants) appears a very promising area of research aiming
to modulate the outcome of the immune system looking for
an impact in the clinics. In this context, several clinical trials
are underway to assess the true efficacy of faecal microbiota
transplantations [10] as well as their long term effects [11, 12].
In agreement with that, there are still many factors regarding
the host/microbiota cross talk which remain obscure and that
have to be addressed to further our understanding about how
the microbiota can modulate the outcome of the immune
responses in the host.
In this special issue, we have therefore aimed to gain
depth into the current understanding of immune processes
in the human gastrointestinal tract in health and disease by
selecting work in progress of active investigators in the field.
The study by C. M. C. Maranduba et al. reviews the most
recent advances on intestinal microbiota and its role in the
maintenance of the host homeostasis. The review describes,
in a detailed manner, the interaction of the microbiota with
the intestinal immune system and the mechanisms involved
in such interaction. The authors also discuss the latest results
on a current hot topic in microbiota research: the interaction
with the nervous system and the impact upon the gut-brain
axis [13]. This research area is attracting increasing attention
for elucidating the impact of the microbiota beyond the
classically studied intestinal interactions, which promises to
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expand our understanding on the role of the microbiota on
human biology in broad terms.
In a similar context, C. Ferreira et al. discuss the impact of
microbes on the gut-associated immune system function and,
moreover, on the onset and development of inflammatory
disorders. An exhaustive revision ofmetagenomic and animal
data in the framework of different diseases, mainly inflam-
matory bowel disease, asthma, and obesity, showed deep
alteration on the gut-associated microbiota profiles, as well
as deficiencies in the immune response. Alterations in the
intestinal microbiota composition promote systemic inflam-
mation that is a hallmark of obesity and subsequent insulin
resistance [14].
Pre- and probiotics have been extensively used for
improving the balance of the intestinal microbiota and
immune response modulation [15, 16]. A human target group
that may benefit very much from strategies aimed at the
modulation of the gut microbiota and the stimulation of the
immune system is that of premature newborns. It is known
that in these infants both the microbiota establishment
process and the immunity are altered. In this issue L. Moles
et al. report the results of a pilot study on the effects of the
administration of two probiotic strains, isolated from human
milk, to preterm infants. The authors evaluated several
microbiological and immunological markers observing the
ability of the strains to modulate the microbiota and to
survive the gastrointestinal passage. Moreover, a reduction
of fecal calprotectin, an inflammatory marker, was observed
throughout the probiotic treatment in agreement with previ-
ous observations [17, 18].
Continuing with the relevance of probiotics, P. Carasi et
al. administered the strain Lactobacillus kefiri CIDCA 8348
to healthy mice during 21 days. This strain was chosen in
a previous study for its ability to induce chemokine CCL20
gene expression, an attractant of immune cells. The overall
impact of L. kefiri on the mouse gut-associated immune
system varied from an increase in fecal IgA to the reduction of
several proinflammatorymediators in Peyer patches. Overex-
pression of interleukin 10 andmucin 6 genes in the ileum and
the ability of L. kefiri to reduce the proinflammatory effects of
lipopolysaccharide make strain CIDCA 8348 a candidate to
be included in functional foods targeting inflammatory bowel
disorders.
We have also selected manuscripts which discuss the role
of themicrobiota not only in immunehomeostasis, but also in
different diseases like HIV and Helicobacter pylori infection.
The gastrointestinal tract has been recently described as
the main HIV reservoir in the human body. While in
healthy controls there is a reciprocal cross talk between the
commensal microbiota and the host, HIV infection can dra-
matically affect both the microbiome and the host’s immune
system adding therefore a third factor to the dialogue in
these patients. In this special issue, K. Vyboh et al. have
reviewed the impact of HIV infection in the gastrointestinal
immune system and how that can lead to changes not only
in the microbiota composition and function, but also in the
mucosal permeability resulting in microbial translocation
from the lumen.As a consequence, viral andmicrobial factors
work together in the patients creating a positive feedback
mechanism which enhances HIV progression leading to a
vicious cycle of immune activation [19, 20].
Helicobacter pylori infection is one of the most common
causes of chronic gastritis. In this issue, L. A. Cherdantseva
et al. performed a histological examination of the gastric
mucosa during development of chronic gastritis in these
patients. Their findings confirmed that H. pylori infection
causes an increase in the number of infiltrating immune cells,
including macrophages and lymphocytes which also had an
enhanced capacity to secrete proinflammatory nitric oxide
synthase which may allow an accumulation of free radicals
in the tissues leading to an aggravation of the inflammatory
process with impaired regeneration processes.
Moving towards more immunologically related studies,
the role of intestinal dendritic cells (DCs) in the gastrointesti-
nal compartment cannot be avoided as they are specialized
antigen-presenting cells with the ability to extend their
dendrites between epithelial cells and directly sample bacteria
from the intestinal content [21, 22]. In a former study, M.
Wiese et al. [23] selected Lactobacillus strains active against
H. pylori. In their new research, the authors used monocyte-
derivedDCs for assessing the immunomodulatory abilities of
those previously selected strains in the presence or absence
of Helicobacter pylori. Both lactobacilli species were able to
increase the maturation of DCs and to induce the production
of IL23. However, the strains differed in their ability to induce
IL-10 leading to different IL-10/IL-12p70 ratios. Altogether,
the results presented suggest that the H. pylori-induced DCs
tolerogenic phenotype may be overcome by the presence of
certain lactobacilli.
Regulatory T-cells (Tregs) are essential to maintain
immune homeostasis as they are critical for prevention of
spontaneous inflammation. While development of Tregs
requires the presence of TGF𝛽 at the time of the antigen
presentation elicited by DCs, the presence of IL-6 promotes
T-cell differentiation towards aTh17 proinflammatory profile
as seen in several autoimmune diseases including rheumatoid
arthritis (RA). In their review, R. Rogier et al. discuss the
mechanisms by which the intestinal microbiota can influence
theTh balance in the lamina propria. To that end, the authors
have reviewed the background information about RA being a
Th17 disease, how the intestinal microbiota can modulate the
outcome of immune responses, and the evidence linking, in
both in vivo and animal models, the commensal microbiota
with RA development likely via TLR recognition by the host.
Continuing with Tregs, information regarding their
development in the neonatal liver is scarce. In their study, A.
Maria et al. describe how Treg can be already found on the
third day after birth in the murine thymus, spleen, and liver.
However, by the first week of life the frequency of liver Treg
cells exceeds that of the spleen by 1.5–2-fold in a transient
manner since 6 weeks after birth frequency of liver Tregs
was reduced. Given that conventionalization of germ-free
animals usually leads to a rapid expansion andmucosal Tregs,
and considering that the liver receives most of its blood flow
via the intestinal portal vein, the authors hypothesized and
proved that the transient increased in neonatal liver Tregs
was controlled by the intestinal microbiota as differences
between frequency of liver and spleen Treg were abrogated
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in MyD88 knockout animals. This study expands our cur-
rent knowledge on how the intestinal microbiota can also
modulate the immune properties of tissues where they do
not get direct access and also about the mechanisms of liver
tolerance development.
As stated before, the intestinal immune system and the
beneficial microorganisms within the lumen of the intestinal
host communicate extensively to eliminate pathogens and
markers to activate the innate and acquired immune response
are necessary. In this issue, K. Radulovic and J. H. Niess
review the role of CD69 which is highly expressed in intesti-
nal T-cells. They propose that not only is this molecule just
an activation marker but also it is essential in the regulation
of intestinal inflammation. They review the evidence about
how microbial-derived factors recognized by pattern recog-
nition receptors could contribute to the CD69 expression
on the surface of colonic T-cells and may be involved in
lymphocyte migration in particular in inflammatory bowel
disease. Although the authors are fully aware that most of the
data come from mice research, they propose that since the
intestinal microflora also regulates this marker in intestinal
inflammation it may be a good target molecule for the
treatment of inflammatory bowel disease.
Finally, an excellent review byM. J. B. Silva et al. covering
many of the aspects described earlier in this editorial and
the mechanisms involved in the modulation of host-microbe
interactions has also been selected. It summarizes the possible
effects of the breakdown of the homeostatic association that
can lead to intestinal inflammation and pathology.
It has been a pleasure to select the work presented in these
areas by experts in the respective fields. We hope that their
findings will help to enrich the knowledge of the mediators
of inflammation of the human gastrointestinal tract and
will form the basis for new approaches to the treatment of
common infections and those conditions that although rare
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